Safety scare cleared and early data in hand, Ultragenyx dishes out $75M to buy rare disease partner - Endpoints News

It had its ups and downs, but Ultragenyx’s three-year-old partnership with an Angelman syndrome-focused biotech has culminated in a buyout. With $75 million upfront, the rare disease specialist is exercising the option it lined up back in 2019 to acquire Gene…

When gene editing exploded onto the scene over three decades ago, it brought previously inconceivable disease treatment and potentially curative therapies into view. Today, gene editing remains one o… [+501 chars]

full article...